About US
Contact us
-
Did Novartis hand out kickbacks or host educational dinners? A jury may decideKickbacks, $10,000 dinners and Hooters. Details that sound pulled from an episode of "Billions" are key accusations in a federal lawsuit against Swiss drugmaker Novartis that could face a jury trial2019/4/3
-
AACR: Clovis' Rubraca follows Lynparza's big pancreatic cancer win with phase 2 dataATLANTA—AstraZeneca and Merck’s Lynparza earlier this year posted an unprecedented phase 3 win in the pancreatic cancer arena. Now, another drug in its class has shown some early success battling the2019/4/2
-
AbbVie's massive Humira discounts are stifling Netherlands biosimilars: reportCould a drug's price ever be too low? That’s what some market-watchers are asking in the Netherlands, where AbbVie is discounting Humira as much as 89%. TheDe Groene Amsterdammerdug intothe procureme2019/4/2
-
Bluebird tees up its first gene therapy approval with Zynteglo thumbs-up in EUBluebird Bio’s development of a gene therapy to treat transfusion-dependent β-thalassemia (TDT) has been far from easy, but the final path to marketis finally coming into view for the 27-year-old com2019/4/1
-
Keytruda nabs key lung cancer nod in China. But are blockbuster sales really attainable?Less than a year after securing its first Chinese approval, in previously treated metastatic melanoma patients, Merck & Co.’s Keytruda has leapt ahead of Bristol-Myers Squibb’s Opdivo and nabbed2019/4/1
-
FDA approves Novartis’ oral multiple sclerosis drug MayzentNovartis has obtained approval from the US Food and Drug Administration (FDA) for its relapsing multiple sclerosis (RMS) drug Mayzent (siponimod). The approval covers indication for secondary progres2019/3/29
-
FDA approves Clarus’ Jatenzo as testosterone replacement therapyClarus Therapeutics has announced that the US Food and Drug Administration (FDA) has approved its oral testosterone undecanoate (TU) Jatenzo for testosterone replacement therapy. The drug is indicate2019/3/29
-
AZ's Farxiga nabbed its Type 1 nod in EU. But after Zynquista's rebuff, how will it fare at FDA?AstraZeneca’s Farxiga just won European approval in Type 1 diabetes, but its prospects in the U.S. are less certain. The FDA’s rejection of Sanofi and Lexicon Pharmaceuticals’ would-be rival Zynquist2019/3/28
-
Can Novartis MS blockbuster-to-be break Mayzent break doctors’ ‘circle of denial’?Novartis officially has approval for Mayzent to treat patients with secondary progressive multiple sclerosis (SPMS). The next challenge? Getting doctors to diagnose it. The FDAgreen-lightedthe produc2019/3/28
-
Forget thinking about 'the patient.' Pharma's shifting to consumer-centric marketing insteadPharma and healthcare aren't just thinking about patients anymore. They're thinking about customers. It's a shiftsimilar to what happened in the tech world in the late ‘80s, says Scott Rabschnuk, who2019/3/27